MZT2B

Summary

MZT2B (mitotic spindle organizing protein 2B, HGNC:25886) is a protein-coding gene on chromosome 2q21.1, encoding Mitotic-spindle organizing protein 2B (Q6NZ67). Required for the recruitment and the assembly of the gamma-tubulin ring complex (gTuRC) at the centrosome.

Located in cytosol; microtubule cytoskeleton; and nucleoplasm. Part of gamma-tubulin ring complex.

Source: NCBI Gene 80097 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 81 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_025029

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25886
Approved symbol	MZT2B
Name	mitotic spindle organizing protein 2B
Location	2q21.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14346, MOZART2B
Ensembl gene	ENSG00000152082
Ensembl biotype	protein_coding
OMIM	613450
Entrez	80097

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000281871, ENST00000409255, ENST00000425361, ENST00000455239, ENST00000457492, ENST00000480182, ENST00000485869, ENST00000491178, ENST00000651060, ENST00000916358, ENST00000916359, ENST00000948926

RefSeq mRNA: 3 — MANE Select: NM_025029 NM_001330282, NM_001330284, NM_025029

CCDS: CCDS2157, CCDS82511

Canonical transcript exons

ENST00000281871 — 3 exons

Exon	Start	End
ENSE00001587901	130182262	130182452
ENSE00002522165	130182627	130182775
ENSE00003556139	130190469	130190727

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 99.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 95.4046 / max 531.0295, expressed in 1827 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
22497	93.9484	1827
22496	1.2633	749
22495	0.1929	63

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.38	gold quality
anterior cingulate cortex	UBERON:0009835	99.31	gold quality
cingulate cortex	UBERON:0003027	99.30	gold quality
amygdala	UBERON:0001876	99.27	gold quality
endocervix	UBERON:0000458	99.20	gold quality
right testis	UBERON:0004534	99.20	gold quality
right frontal lobe	UBERON:0002810	99.16	gold quality
left testis	UBERON:0004533	99.16	gold quality
left ovary	UBERON:0002119	99.14	gold quality
body of pancreas	UBERON:0001150	99.11	gold quality
right ovary	UBERON:0002118	99.06	gold quality
left lobe of thyroid gland	UBERON:0001120	99.05	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.03	gold quality
prefrontal cortex	UBERON:0000451	99.02	gold quality
left uterine tube	UBERON:0001303	99.02	gold quality
nucleus accumbens	UBERON:0001882	99.02	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.01	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.99	gold quality
right lobe of thyroid gland	UBERON:0001119	98.98	gold quality
mucosa of stomach	UBERON:0001199	98.97	gold quality
heart left ventricle	UBERON:0002084	98.97	gold quality
lower esophagus	UBERON:0013473	98.97	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.97	gold quality
lower esophagus mucosa	UBERON:0035834	98.97	gold quality
body of stomach	UBERON:0001161	98.96	gold quality
mucosa of transverse colon	UBERON:0004991	98.94	gold quality
cardiac ventricle	UBERON:0002082	98.93	gold quality
right atrium auricular region	UBERON:0006631	98.92	gold quality
body of uterus	UBERON:0009853	98.92	gold quality
left adrenal gland cortex	UBERON:0035825	98.91	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	344.54
E-CURD-46	yes	19.67
E-ANND-3	yes	16.15
E-MTAB-10553	yes	7.32
E-CURD-88	yes	5.35
E-CURD-122	yes	4.69
E-MTAB-7008	no	115.28
E-GEOD-124858	no	52.66
E-GEOD-125970	no	15.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

4 targeting MZT2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-6810-5P	98.29	66.21	975
HSA-MIR-4330	95.44	66.39	993

Literature-anchored findings (GeneRIF, showing 1)

• MZT Proteins Form Multi-Faceted Structural Modules in the gamma-Tubulin Ring Complex. (PMID:32610146)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mzt2b	ENSDARG00000057928
mus_musculus	Mzt2	ENSMUSG00000022671
rattus_norvegicus	Mzt2b	ENSRNOG00000066842

Paralogs (1): MZT2A (ENSG00000173272)

Protein

Protein identifiers

Mitotic-spindle organizing protein 2B — Q6NZ67 (reviewed: Q6NZ67)

Alternative names: Mitotic-spindle organizing protein associated with a ring of gamma-tubulin 2B

All UniProt accessions (6): Q6NZ67, A0A494C0V9, B8ZZ87, H7BZ50, H7C173, H7C293

UniProt curated annotations — full annotation on UniProt →

Function. Required for the recruitment and the assembly of the gamma-tubulin ring complex (gTuRC) at the centrosome. The gTuRC regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments, a critical step in centrosome duplication and spindle formation.

Subunit / interactions. Associates with the gamma-tubulin ring complex (gTuRC) consisting of TUBGCP2, TUBGCP3, TUBGCP4, TUBGCP5 and TUBGCP6 and gamma-tubulin TUBG1 or TUBG2; within the complex, interacts with TUBGCP2; the interaction plays a role in gTuRC activation. Interacts with TUBG1.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle.

Similarity. Belongs to the MOZART2 family.

RefSeq proteins (3): NP_001317211, NP_001317213, NP_079305* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024332	MOZART2	Family

Pfam: PF12926

UniProt features (8 total): compositionally biased region 2, modified residue 2, sequence variant 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9QVM	ELECTRON MICROSCOPY	6.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NZ67-F1	64.86	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 34, 152

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes
R-HSA-1640170	Cell Cycle
R-HSA-380287	Centrosome maturation
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-68877	Mitotic Prometaphase
R-HSA-68886	M Phase
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 136 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_MICROTUBULE_NUCLEATION, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOCC_CENTROSOME, CREB_Q3, GOBP_MICROTUBULE_POLYMERIZATION, GOCC_SPINDLE, GOCC_GAMMA_TUBULIN_COMPLEX, KIM_WT1_TARGETS_DN, CHEN_METABOLIC_SYNDROM_NETWORK, TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C, GOBP_MICROTUBULE_CYTOSKELETON_ORGANIZATION, KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3, GOBP_PROTEIN_POLYMERIZATION, GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): gamma-tubulin ring complex (GO:0000931), nucleoplasm (GO:0005654), centrosome (GO:0005813), spindle (GO:0005819), cytosol (GO:0005829), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Cell Cycle, Mitotic	2
Centrosome maturation	1
Mitotic Prometaphase	1
G2/M Transition	1
M Phase	1
Mitotic G2-G2/M phases	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular membraneless organelle	2
binding	1
gamma-tubulin complex	1
gamma-tubulin small complex	1
nuclear lumen	1
centriole	1
microtubule organizing center	1
microtubule cytoskeleton	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

104 interactions, top by confidence:

A	B	Type	Score
CSNK1A1	FAM83G	psi-mi:“MI:0914”(association)	0.900
ODAD1	HGS	psi-mi:“MI:0914”(association)	0.850
TUBGCP5	TUBG1	psi-mi:“MI:0914”(association)	0.840
MZT2B	TUBG1	psi-mi:“MI:0914”(association)	0.770
TUBG1	MZT2B	psi-mi:“MI:0915”(physical association)	0.770
Mzt2	TUBG1	psi-mi:“MI:0914”(association)	0.560
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
NPY2R	RTL8C	psi-mi:“MI:0914”(association)	0.530
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
TUBG2	TXNDC9	psi-mi:“MI:0914”(association)	0.530
SLCO1B1	SYNGR2	psi-mi:“MI:0914”(association)	0.530
MZT1	PCNT	psi-mi:“MI:0914”(association)	0.530
TXNDC12	TUBG1	psi-mi:“MI:0914”(association)	0.530
CXCR4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
FBXW11	AHCYL1	psi-mi:“MI:0914”(association)	0.530
TUBG2	TCP1	psi-mi:“MI:0914”(association)	0.530
NEDD1	CEP290	psi-mi:“MI:0914”(association)	0.480
Tubgcp3		psi-mi:“MI:0915”(physical association)	0.400
Mzt2		psi-mi:“MI:0915”(physical association)	0.400
Tubgcp2	TUBG1	psi-mi:“MI:0915”(physical association)	0.400
Tubg1		psi-mi:“MI:0915”(physical association)	0.400

BioGRID (137): MZT2B (Affinity Capture-MS), TUBGCP2 (Affinity Capture-MS), TUBG1 (Affinity Capture-MS), TUBGCP5 (Affinity Capture-MS), TUBGCP3 (Affinity Capture-MS), TUBGCP6 (Affinity Capture-MS), TUBGCP4 (Affinity Capture-MS), NME7 (Affinity Capture-MS), MZT2B (Affinity Capture-MS), MZT2B (Co-fractionation), MZT2B (Biochemical Activity), MZT2B (Affinity Capture-MS), MZT2B (Affinity Capture-MS), MZT2B (Affinity Capture-MS), MZT2B (Affinity Capture-MS)

ESM2 similar proteins: A4D2P6, A5PJV8, A6NFD8, D4AE48, O00268, O00287, O35274, O35779, O43566, P04198, P12755, P55199, Q08DA0, Q0D2I5, Q2KJ58, Q504T8, Q5XKK7, Q60698, Q61976, Q6NZ67, Q6P582, Q6R891, Q6T4P5, Q7Z6J2, Q80YR4, Q86UD0, Q86UK7, Q8BXL9, Q8CEG5, Q8R4T5, Q8TF61, Q8VCG9, Q969F2, Q969G9, Q96HZ4, Q96SB3, Q99PV5, Q9BQ61, Q9BUN5, Q9BZE9

Diamond homologs: A5PJV8, Q28DB1, Q6DC17, Q6NZ67, Q6P582, Q9CQ25

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 129 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of vitamins, nucleosides, and related molecules	6	20.9×	8e-05
Recruitment of mitotic centrosome proteins and complexes	11	19.2×	6e-09
Recruitment of NuMA to mitotic centrosomes	11	16.4×	2e-08
Centrosome maturation	5	16.3×	2e-03
Regulation of PLK1 Activity at G2/M Transition	6	9.8×	4e-03
G alpha (i) signalling events	10	5.0×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
microtubule nucleation	8	47.1×	3e-09
cytoplasmic microtubule organization	7	22.7×	8e-06
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	5	15.9×	2e-03
mitotic cell cycle	7	8.8×	2e-03
G protein-coupled receptor signaling pathway	13	4.4×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	59
Likely benign	12
Benign	4

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
4279388	GRCh37/hg19 2q21.1(chr2:130904460-131041207)x1	Pathogenic
183299	NM_207312.3(TUBA3E):c.643C>T (p.Arg215Cys)	Likely pathogenic

SpliceAI

709 predictions. Top by Δscore:

Variant	Effect	Δscore
2:130182446:TGTTC:T	donor_gain	1.0000
2:130182448:TTC:T	donor_gain	1.0000
2:130182453:G:GG	donor_gain	1.0000
2:130182447:GTTCA:G	donor_gain	0.9900
2:130182452:AG:A	donor_loss	0.9900
2:130182454:T:G	donor_loss	0.9900
2:130182771:CCGAG:C	donor_loss	0.9900
2:130182772:CGAG:C	donor_loss	0.9900
2:130182773:GAGGT:G	donor_loss	0.9900
2:130182774:AG:A	donor_loss	0.9900
2:130182775:GG:G	donor_loss	0.9900
2:130182776:G:A	donor_loss	0.9900
2:130182777:T:G	donor_loss	0.9900
2:130183667:G:T	donor_gain	0.9900
2:130190463:CCTCA:C	acceptor_loss	0.9900
2:130190464:CTCA:C	acceptor_loss	0.9900
2:130190465:TCAGG:T	acceptor_loss	0.9900
2:130190467:A:AC	acceptor_loss	0.9900
2:130190467:A:AG	acceptor_gain	0.9900
2:130190467:AG:A	acceptor_gain	0.9900
2:130190468:G:GG	acceptor_gain	0.9900
2:130190468:GG:G	acceptor_gain	0.9900
2:130190468:GGGA:G	acceptor_gain	0.9900
2:130182399:GCT:G	donor_gain	0.9800
2:130182442:G:GT	donor_gain	0.9800
2:130182455:GA:G	donor_loss	0.9800
2:130182553:T:TA	donor_gain	0.9800
2:130182625:AG:A	acceptor_gain	0.9800
2:130182626:GG:G	acceptor_gain	0.9800
2:130190466:CAGGG:C	acceptor_gain	0.9800

AlphaMissense

998 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:130182641:T:C	L62P	0.999
2:130182671:T:A	V72D	0.999
2:130182683:T:A	L76H	0.999
2:130182410:T:C	L43P	0.998
2:130182644:T:C	L63P	0.998
2:130182683:T:C	L76P	0.998
2:130182401:T:C	L40P	0.997
2:130182449:T:C	F56S	0.997
2:130182641:T:A	L62Q	0.997
2:130182662:C:A	P69H	0.997
2:130182668:C:A	A71D	0.997
2:130182448:T:C	F56L	0.996
2:130182450:C:A	F56L	0.996
2:130182450:C:G	F56L	0.996
2:130182629:T:C	I58T	0.996
2:130182650:T:C	L65P	0.996
2:130182653:A:T	N66I	0.996
2:130182662:C:G	P69R	0.996
2:130182662:C:T	P69L	0.996
2:130182401:T:A	L40Q	0.995
2:130182410:T:A	L43Q	0.995
2:130182629:T:G	I58S	0.995
2:130182632:T:C	L59P	0.995
2:130182680:T:G	M75R	0.995
2:130182683:T:G	L76R	0.995
2:130182418:G:C	A46P	0.994
2:130182627:G:C	K57N	0.994
2:130182627:G:T	K57N	0.994
2:130182661:C:A	P69T	0.994
2:130182421:G:C	A47P	0.993

dbSNP variants (sampled 300 via entrez): RS1000136066 (2:130180891 G>T), RS1000227143 (2:130193270 A>T), RS1000510490 (2:130194562 G>C), RS1000536099 (2:130182056 G>A,C), RS1000711336 (2:130186299 A>G), RS1001043467 (2:130181863 T>A,C), RS1001308731 (2:130186057 C>G), RS1001412457 (2:130185672 C>G,T), RS1001758608 (2:130181300 C>A,G,T), RS1001839542 (2:130190162 A>G), RS1002147837 (2:130182399 G>A), RS1002231239 (2:130203312 C>T), RS1003011961 (2:130196529 C>A,T), RS1003107553 (2:130190922 C>T), RS1003273172 (2:130187918 C>G)

Disease associations

OMIM: gene MIM:613450 | disease phenotypes: MIM:607432

GenCC curated gene-disease

Mondo (2): lissencephaly spectrum disorders (MONDO:0018838), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Lissencephaly (Orphanet:48471)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001339	Lissencephaly

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D054082	Lissencephaly	C10.500.507.450.499; C16.131.666.507.450.499
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, affects binding, increases reaction, decreases expression	3
Valproic Acid	affects expression, decreases expression	3
FR900359	increases phosphorylation	1
methylmercuric chloride	increases expression	1
bisphenol A	affects expression	1
glycidyl methacrylate	increases expression	1
lead acetate	increases expression, affects cotreatment	1
tris(2-butoxyethyl) phosphate	affects expression	1
zinc protoporphyrin	affects cotreatment, increases expression	1
butyraldehyde	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Benzo(a)pyrene	affects expression	1
Cisplatin	decreases expression	1
Lead	increases expression	1
Lipopolysaccharides	affects expression, affects response to substance	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Cyclosporine	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3BQ	Abcam HEK293T MZT2B KO	Transformed cell line	Female

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice